S&P 500   4,117.86
DOW   33,949.01
QQQ   304.37
Is SoundHound Voice AI the Next Big Thing?
Free Stock Analysis Report: Get Buy, Sell, or Hold Recommendation (Ad)pixel
CVS Health Corporation Is Coiled And Ready To Spring Higher 
Double Meat: Beyond Meat Could Be 2023’s Next Two-Bagger
An All-In-One Guide for Trading Metals (Ad)pixel
3 Solar-Energy Stocks Setting Up In Bullish Bases
V.F. Corporation Is A High-Yield Bargain Despite Dividend Cut
An All-In-One Guide for Trading Metals (Ad)pixel
TG Therapeutics Stock 300% Rally Has Legs Yet
Daqo New Energy Charged Up For New Highs
S&P 500   4,117.86
DOW   33,949.01
QQQ   304.37
Is SoundHound Voice AI the Next Big Thing?
Free Stock Analysis Report: Get Buy, Sell, or Hold Recommendation (Ad)pixel
CVS Health Corporation Is Coiled And Ready To Spring Higher 
Double Meat: Beyond Meat Could Be 2023’s Next Two-Bagger
An All-In-One Guide for Trading Metals (Ad)pixel
3 Solar-Energy Stocks Setting Up In Bullish Bases
V.F. Corporation Is A High-Yield Bargain Despite Dividend Cut
An All-In-One Guide for Trading Metals (Ad)pixel
TG Therapeutics Stock 300% Rally Has Legs Yet
Daqo New Energy Charged Up For New Highs
S&P 500   4,117.86
DOW   33,949.01
QQQ   304.37
Is SoundHound Voice AI the Next Big Thing?
Free Stock Analysis Report: Get Buy, Sell, or Hold Recommendation (Ad)pixel
CVS Health Corporation Is Coiled And Ready To Spring Higher 
Double Meat: Beyond Meat Could Be 2023’s Next Two-Bagger
An All-In-One Guide for Trading Metals (Ad)pixel
3 Solar-Energy Stocks Setting Up In Bullish Bases
V.F. Corporation Is A High-Yield Bargain Despite Dividend Cut
An All-In-One Guide for Trading Metals (Ad)pixel
TG Therapeutics Stock 300% Rally Has Legs Yet
Daqo New Energy Charged Up For New Highs
S&P 500   4,117.86
DOW   33,949.01
QQQ   304.37
Is SoundHound Voice AI the Next Big Thing?
Free Stock Analysis Report: Get Buy, Sell, or Hold Recommendation (Ad)pixel
CVS Health Corporation Is Coiled And Ready To Spring Higher 
Double Meat: Beyond Meat Could Be 2023’s Next Two-Bagger
An All-In-One Guide for Trading Metals (Ad)pixel
3 Solar-Energy Stocks Setting Up In Bullish Bases
V.F. Corporation Is A High-Yield Bargain Despite Dividend Cut
An All-In-One Guide for Trading Metals (Ad)pixel
TG Therapeutics Stock 300% Rally Has Legs Yet
Daqo New Energy Charged Up For New Highs
NASDAQ:DRRX

DURECT - DRRX Stock Forecast, Price & News

$5.81
-0.38 (-6.14%)
(As of 02/8/2023 12:00 AM ET)
Add
Compare
Today's Range
$5.63
$6.27
50-Day Range
$3.39
$8.72
52-Week Range
$3.16
$9.70
Volume
84,076 shs
Average Volume
110,988 shs
Market Capitalization
$132.41 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$32.00

DURECT MarketRank™ Forecast

Analyst Rating
N/A
0.00 Rating Score
Upside/​Downside
450.8% Upside
$32.00 Price Target
Short Interest
Bearish
1.43% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.19
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.62) to ($1.71) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.44 out of 5 stars

Medical Sector

956th out of 1,026 stocks

Pharmaceutical Preparations Industry

466th out of 504 stocks

DRRX stock logo

About DURECT (NASDAQ:DRRX) Stock

DURECT Corp. focuses on advancing novel and potentially lifesaving investigational therapies derived from its Epigenetic Regulator Program. Its pipeline is called DUR-928, an endogenous sulfated oxysterol and an epigenetic regulator. The company was founded by James E. Brown and Felix Theeuwes on February 6, 1998 and is headquartered in Cupertino, CA.

Receive DRRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DURECT and its competitors with MarketBeat's FREE daily newsletter.

DRRX Stock News Headlines

Durect (NASDAQ: DRRX)
Preparing Your Investment Portfolio for the Recession is easy as 1-2-3.
In a recession, traditional asset classes are vulnerable to significant price volatility. But, wealthy investors seek safe haven during these crises by investing in tangible assets like fine art. It outpaced the S&P 500 by more than 2x in the last 25 years, while having lower volatility than public markets.  With Masterworks, it's easy for anyone to invest in art. Get started today with a special link. **See important disclosures pixel
DURECT Announces 1-for-10 Reverse Stock Split
DURECT (NASDAQ:DRRX) Research Coverage Started at StockNews.com
These 5 Tech Stocks Have 10x Potential
If you had bought Netflix after the dot-com crash, you could have turned $1,000 into over half a million dollars in profit. And today – thanks to the text crash – you have a similar opportunity. Luke Lango just named 5 tech stocks with 10x potential in a new report (one is trading for just $6). Click here to claim your copy. pixel
Innocoll and DURECT Announce U.S. launch of POSIMIR®
See More Headlines
Receive DRRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DURECT and its competitors with MarketBeat's FREE daily newsletter.

DRRX Company Calendar

Last Earnings
11/01/2021
Today
2/08/2023
Next Earnings (Estimated)
3/06/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:DRRX
Employees
79
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$32.00
High Stock Price Forecast
$32.00
Low Stock Price Forecast
$32.00
Forecasted Upside/Downside
+450.8%
Consensus Rating
N/A
Rating Score (0-4)
0.00
Research Coverage
0 Analysts

Profitability

Net Income
$-36,260,000.00
Net Margins
-136.99%
Pretax Margin
-136.99%

Debt

Sales & Book Value

Annual Sales
$13.98 million
Book Value
$2.54 per share

Miscellaneous

Free Float
21,761,000
Market Cap
$132.41 million
Optionable
Optionable
Beta
1.40

Key Executives

  • James E. Brown
    President, Chief Executive Officer & Director
  • Judy R. Joice
    Senior VP-Operations & Corporate Quality Assurance
  • Timothy M Papp
    Chief Financial Officer & Secretary
  • Wei Qi Lin
    Executive Vice President-Research & Development
  • David J. Ellis
    Vice President-Clinical Development













DRRX Stock - Frequently Asked Questions

What is DURECT's stock price forecast for 2023?

0 brokerages have issued 12-month price objectives for DURECT's shares. Their DRRX share price forecasts range from $32.00 to $32.00. On average, they expect the company's stock price to reach $32.00 in the next year. This suggests a possible upside of 450.8% from the stock's current price.
View analysts price targets for DRRX
or view top-rated stocks among Wall Street analysts.

How have DRRX shares performed in 2023?

DURECT's stock was trading at $3.46 on January 1st, 2023. Since then, DRRX shares have increased by 67.9% and is now trading at $5.81.
View the best growth stocks for 2023 here
.

When is DURECT's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 6th 2023.
View our DRRX earnings forecast
.

How were DURECT's earnings last quarter?

DURECT Co. (NASDAQ:DRRX) announced its quarterly earnings results on Monday, November, 1st. The specialty pharmaceutical company reported ($0.40) EPS for the quarter, beating analysts' consensus estimates of ($0.50) by $0.10. The specialty pharmaceutical company earned $2.17 million during the quarter, compared to analysts' expectations of $2.18 million. DURECT had a negative net margin of 136.99% and a negative trailing twelve-month return on equity of 72.05%. During the same quarter last year, the business posted ($0.50) earnings per share.

When did DURECT's stock split?

DURECT's stock reverse split on the morning of Tuesday, December 6th 2022. The 1-10 reverse split was announced on Tuesday, December 6th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, December 6th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of DURECT own?

Based on aggregate information from My MarketBeat watchlists, some companies that other DURECT investors own include Geron (GERN), Catalyst Pharmaceuticals (CPRX), VBI Vaccines (VBIV), MannKind (MNKD), Novavax (NVAX), Cassava Sciences (SAVA), Amarin (AMRN), Matinas BioPharma (MTNB), Inovio Pharmaceuticals (INO) and Verastem (VSTM).

What is DURECT's stock symbol?

DURECT trades on the NASDAQ under the ticker symbol "DRRX."

Who are DURECT's major shareholders?

DURECT's stock is owned by a variety of institutional and retail investors. Top institutional investors include Ingalls & Snyder LLC (4.01%), Beirne Wealth Consulting Services LLC (1.03%), Gagnon Securities LLC (0.68%), Ironwood Investment Management LLC (0.37%), Cowen Prime Advisors LLC (0.21%) and Raymond James & Associates (0.08%). Insiders that own company stock include Gail J Maderis, Gail M Farfel, Judith J Robertson, Judy R Joice, Lp Bleichroeder, Mohammad Azab and Simon X Benito.
View institutional ownership trends
.

How do I buy shares of DURECT?

Shares of DRRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is DURECT's stock price today?

One share of DRRX stock can currently be purchased for approximately $5.81.

How much money does DURECT make?

DURECT (NASDAQ:DRRX) has a market capitalization of $132.41 million and generates $13.98 million in revenue each year. The specialty pharmaceutical company earns $-36,260,000.00 in net income (profit) each year or ($1.40) on an earnings per share basis.

How can I contact DURECT?

DURECT's mailing address is 10260 BUBB RD, CUPERTINO CA, 95014. The official website for the company is www.durect.com. The specialty pharmaceutical company can be reached via phone at (408) 777-1417, via email at mike.arenberg@durect.com, or via fax at 408-777-3577.

This page (NASDAQ:DRRX) was last updated on 2/9/2023 by MarketBeat.com Staff